# DNLI catalysts: Denali Therapeutics Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/dnli/catalysts

> Denali Therapeutics Inc. (DNLI) has 9 upcoming catalysts. The next is the zafinofusp alfa NDA/BLA submission, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for DNLI?

Denali Therapeutics Inc. (DNLI) has 9 upcoming catalysts. The next is the zafinofusp alfa NDA/BLA submission, 2027. Press release filed with the SEC (EX-99): "•Zafinofusp alfa advancing as Denali's second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA)" [Calendar and source filings](https://sec-api.dev/companies/dnli/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001714899-26-000107, https://www.sec.gov/Archives/edgar/data/1714899/000171489926000107/ex991pressreleaseq32026.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/companies/dnli/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Denali Therapeutics Inc. |
| Ticker | DNLI (Nasdaq) |
| SEC CIK | 1714899 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/dnli |

## Cash runway

Cash $1.01B as of 2026-09-30; quarterly burn $117.4M; about 25.7 months of runway at that rate (XBRL company facts, accession 0001714899-26-000109).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [DNL126 trial start](https://sec-api.dev/pdufa/dnl126) | DNLI |  | completed | "◦In February 2024, we announced that dosing had been initiated in the Phase 1/2 study of DNL126 in MPS IIIA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm)) |
| February 27, 2025 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000067/ex991pressreleaseq42024.htm)) |
| May 2025 | [Tividenofusp alfa NDA/BLA submission](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Hunter syndrome in late 2025 or early 2026 | scheduled | "Denali expects to complete the BLA submission in the first half of May 2025 and continues to prepare for a potential commercial launch in the U.S. in late 2025 or early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000077/exhibit991pressrelease4220.htm)) |
| May 6, 2025 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000104/ex991pressreleaseq12025.htm)) |
| July 7, 2025 | [Tividenofusp alfa NDA/BLA acceptance](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Hunter syndrome | completed | "SOUTH SAN FRANCISCO, Calif., - July 7, 2025 - Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for tividenofusp alfa for the treatment of Hunter syndrome (mucopolysaccharidoses type II, or MPS II), a rare and progressive genetic disorder." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/exhibit991pressrelease7720.htm)) |
| August 11, 2025 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000167/ex991pressreleaseq22025.htm)) |
| October 13, 2025 | [Tividenofusp alfa PDUFA date](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | mucopolysaccharidosis type II | scheduled | "On October 13, 2025, Denali Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for the Company's Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000180/dnli-20251013.htm)) |
| November 6, 2025 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000192/ex991pressreleaseq32025.htm)) |
| January 5, 2026 | [Tividenofusp PDUFA date](https://sec-api.dev/pdufa/tividenofusp) | DNLI |  | scheduled | "•FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/exhibit991pressrelease7720.htm)) |
| February 26, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm)) |
| Mar 2026 | [DNL628 trial start](https://sec-api.dev/pdufa/dnl628) | DNLI |  | completed | "In March 2026, the first patient was dosed in the Phase 1b study of DNL628, which is an investigational therapy for Alzheimer's disease and enabled by Denali's Oligonucleotide TransportVehicle™ (OTV)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000062/ex991pressreleaseq12026.htm)) |
| March 24, 2026 | [Avlayah (tividenofusp alfa-eknm) FDA approval](https://sec-api.dev/pdufa/tividenofusp-alfa-eknm) | DNLI |  | completed, approved | "Avlayah \| tividenofusp alfa-eknm \| 3/24/2026 \| To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| March 25, 2026 | [Tividenofusp alfa FDA approval](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | of neurologic manifestations in patients with Hunter syndrome | completed, approved | "On March 25, 2026, Denali Therapeutics Inc., a Delaware corporation (the "Company"), issued a press release announcing that the U.S. Food and Drug Administration approved AVLAYAHTM (tividenofusp alfa) for the treatment of of neurologic manifestations in patients with Hunter syndrome (MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000030/dnli-20260325.htm)) |
| April 5, 2026 | [Tividenofusp PDUFA date](https://sec-api.dev/pdufa/tividenofusp) | DNLI |  | scheduled | "58 Tividenofusp Alfa Development and Regulatory Path Robust data package supporting a target indication for the full MPS II phenotype spectrum PDUFA Target Action Date: April 5, 2026 Preparing for Commercial Launch" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000209/a20251204-denaliinvestor.htm)) |
| April 5, 2026 | [Tividenofusp alfa PDUFA date](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI |  | completed, approved | "•Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm)) |
| May 7, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000062/ex991pressreleaseq12026.htm)) |
| Jun 2026 | [DNL593 FDA approval](https://sec-api.dev/pdufa/dnl593) | DNLI |  | completed, approved | "In June 2026, Denali entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV), awarded following the FDA approval of AVLAYAH, for gross proceeds of $195 million." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/ex991pressreleaseq22026.htm)) |
| Aug 2026 | [DNL921 trial start](https://sec-api.dev/pdufa/dnl921) | DNLI |  | completed | "•In the first half of 2026, we submitted a clinical trial application to initiate a Phase 1/1b study of DNL921 (ATV:Abeta) in healthy volunteers and participants with Alzheimer's disease, and the first healthy volunteer was dosed in August 2026; and" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000109/dnli-20260930.htm)) |
| August 6, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/ex991pressreleaseq22026.htm)) |
| November 3, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000107/ex991pressreleaseq32026.htm)) |
| 2027 | [Zafinofusp alfa NDA/BLA submission](https://sec-api.dev/pdufa/zafinofusp-alfa) | DNLI |  | scheduled | "•Zafinofusp alfa advancing as Denali's second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000107/ex991pressreleaseq32026.htm)) |
| 2027 | [DNL952 interim data readout](https://sec-api.dev/pdufa/dnl952) | DNLI |  | scheduled | "The Phase 1 study of DNL952 is enrolling participants with late-onset Pompe disease (LOPD), and initial clinical data are expected in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000107/ex991pressreleaseq32026.htm)) |
| 2027 | [DNL126 NDA/BLA submission](https://sec-api.dev/pdufa/dnl126) | DNLI |  | scheduled | "64 Study Data for the DNL126 Accelerated Approval BLA - Biologics licensing application; AA - Accelerated approval; CSF - Cerebrospinal fluid; HS - Heparan sulfate Expected BLA submission and approval in 2027 Data for BLA Submission" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000209/a20251204-denaliinvestor.htm)) |
| March 2027 | [Biib122 225 mg primary completion](https://sec-api.dev/pdufa/biib122) | DNLI | Parkinson Disease | scheduled | "NCT06602193 (Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602193)) |
| Mar to Jun 2027 | [Biib122 225 mg topline data readout](https://sec-api.dev/pdufa/biib122) | DNLI | Parkinson Disease | scheduled | "NCT06602193 (Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602193)) |
| June 2027 | [Tividenofusp alfa primary completion](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT06075537 (An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075537)) |
| Jun to Sep 2027 | [Tividenofusp alfa topline data readout](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT06075537 (An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075537)) |
| December 2027 | [Tividenofusp alfa primary completion](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT05371613 (A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371613)) |
| Dec 2027 to Mar 2028 | [Tividenofusp alfa topline data readout](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Mucopolysaccharidosis II | scheduled | "NCT05371613 (A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371613)) |

## Drugs

- [DNL126](https://sec-api.dev/pdufa/dnl126): 
- [DNL593](https://sec-api.dev/pdufa/dnl593): 
- [DNL628](https://sec-api.dev/pdufa/dnl628): 
- [DNL921](https://sec-api.dev/pdufa/dnl921): 
- [DNL952](https://sec-api.dev/pdufa/dnl952): 
- [Tividenofusp](https://sec-api.dev/pdufa/tividenofusp): 
- [Tividenofusp alfa](https://sec-api.dev/pdufa/tividenofusp-alfa): hunter syndrome, of neurologic manifestations in patients with hunter syndrome, mucopolysaccharidosis type ii, hunter syndrome in late 2025 or early 2026, Mucopolysaccharidosis II
- [Avlayah (tividenofusp alfa-eknm)](https://sec-api.dev/pdufa/tividenofusp-alfa-eknm): 
- [Zafinofusp alfa](https://sec-api.dev/pdufa/zafinofusp-alfa): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/dnli/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DNLI catalysts: Denali Therapeutics Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/dnli/catalysts

```bibtex
@misc{secapidev_companies_dnli_catalysts_20261116,
  title        = {DNLI catalysts: Denali Therapeutics Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/dnli/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_dnli_catalysts_20261116","title":"DNLI catalysts: Denali Therapeutics Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/dnli/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
